[HTML][HTML] Crizotinib in patients with MET-amplified NSCLC
DR Camidge, GA Otterson, JW Clark, SHI Ou… - Journal of Thoracic …, 2021 - Elsevier
Introduction MET amplification is a rare, potentially actionable, primary oncogenic driver in
patients with NSCLC. Methods The influence of MET amplification on the clinical activity of …
patients with NSCLC. Methods The influence of MET amplification on the clinical activity of …
Crizotinib in Patients With MET-Amplified NSCLC
DR Camidge, GA Otterson, JW Clark… - Journal of thoracic …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction MET amplification is a rare, potentially actionable, primary oncogenic driver in
patients with NSCLC. Methods The influence of MET amplification on the clinical activity of …
patients with NSCLC. Methods The influence of MET amplification on the clinical activity of …
[HTML][HTML] Crizotinib in Patients With MET-Amplified NSCLC
DR Camidge, GA Otterson, JW Clark, SHI Ou… - Journal of Thoracic …, 2021 - jto.org
Introduction MET amplification is a rare, potentially actionable, primary oncogenic driver in
patients with NSCLC. Methods The influence of MET amplification on the clinical activity of …
patients with NSCLC. Methods The influence of MET amplification on the clinical activity of …
[引用][C] Crizotinib in Patients With MET-Amplified NSCLC
DR Camidge, GA Otterson, JW Clark, SHI Ou… - Journal of Thoracic …, 2021 - cir.nii.ac.jp
Crizotinib in Patients With MET-Amplified NSCLC.
DR Camidge, GA Otterson, JW Clark, IO SH… - Journal of Thoracic …, 2021 - europepmc.org
Methods The influence of MET amplification on the clinical activity of the ALK, ROS1, and
MET inhibitor, crizotinib (250 mg twice daily), was examined in patients with NSCLC …
MET inhibitor, crizotinib (250 mg twice daily), was examined in patients with NSCLC …
Crizotinib in Patients With MET-Amplified NSCLC
DR Camidge, GA Otterson… - Journal of …, 2021 - ohiostate.elsevierpure.com
Introduction: MET amplification is a rare, potentially actionable, primary oncogenic driver in
patients with NSCLC. Methods: The influence of MET amplification on the clinical activity of …
patients with NSCLC. Methods: The influence of MET amplification on the clinical activity of …